# Merkel Cell Carcinoma: A Complete Response to Avelumab Immunotherapy

## TL;DR

A patient with aggressive Merkel cell carcinoma achieved a complete response to avelumab immunotherapy, showing promise for long-term outcomes.

## Contribution

Demonstrates the effectiveness of avelumab in achieving a complete response in Merkel cell carcinoma.

## Key findings

- Avelumab immunotherapy led to a complete response in a Merkel cell carcinoma patient.
- Improved long-term outcomes are possible with immunotherapy even for palliative cases.

## Abstract

Merkel cell carcinoma is an aggressive form of cancer with poor prognosis, particularly for individuals deemed unsuitable for surgical resection. With new immunotherapy agents being used alone or as an adjuvant treatment, improving long term outcomes are being seen, even for those deemed to be treated with palliative intent.